Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

Abstract: The present invention relates to antibodies specific for pyroglutamated A?, as well as their use in the treatment of Alzheimer's disease and as use in diagnostic methods or as diagnostic imaging ligands. Further, is provided pyroglutamated N-terminal fragments of murine or human A? to generate antibodies and for use in therapeutic purposes.

Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

Abstract: The present invention relates to an anti-Notch 3 antibody therapy useful for treatment of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. In particular, the invention relates to an anti-Notch3 antibody or a fragment thereof having a 2 fold, 4 fold or 10 fold higher affinity to Notch 3 than to Notch 1 or Notch 2 for use in therapy.

Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.

Abstract: The present invention relates to a novel class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396), as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and tauopathies.

Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).

Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

Abstract: A method of determining a representation of a physical property of a finger using a finger sensing system comprising a two-dimensional measuring arrangement including a plurality of measuring elements, each defining a measuring element position in the measuring arrangement, and each comprising a finger electrode spaced apart from the finger by a dielectric structure.

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).

Abstract: The present invention relates to an anti-Notch 3 antibody therapy useful for treatment of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. In particular, the invention relates to an anti-Notch3 antibody or a fragment thereof having a 2 fold, 4 fold or 10 fold higher affinity to Notch 3 than to Notch 1 or Notch 2 for use in therapy.

Abstract: The present invention relates to antibodies specific for pyroglutamated A?, as well as their use in the treatment of Alzheimer's disease and as use in diagnostic methods or as diagnostic imaging ligands. Further, is provided pyroglutamated N-terminal fragments of murine or human A? to generate antibodies and for use in therapeutic purposes.

Abstract: The present disclosure relates to antibodies specific for pyroglutamated A?, as well as their use in the treatment of Alzheimer's disease and as use in diagnostic methods or as diagnostic imaging ligands Further, is provided pyroglutamated N-terminal fragments of murine or human A? to generate antibodies and for use m therapeutic purposes.

Abstract: A computer-implemented method of identifying vascular territories in an imaging volume representing an anatomical region, including: obtaining, for each volume element of a plurality of volume elements into which the imaging volume is divided, arrival time data representing an estimated arrival time of a contrast agent at the volume element; defining one or more seed regions, each seed region associated with one of a plurality of vascular territories and containing seed volume elements for which the estimated arrival time does not exceed a threshold time; identifying, on the basis of the arrival time data, unassigned elements of the plurality of volume elements which are connected with a seed volume element; and assigning said unassigned elements of the plurality of volume elements to one of said vascular territories.

Abstract: A hearing aid (1) comprising a receiver (2) and at least one first microphone for transforming an acoustic signal surrounding a hearing aid user into an electrical signal, where the hearing aid comprises an ear plug part prepared for fitting tightly into the car canal (11) of a hearing aid user such that an inner volume is formed in the inner part of the ear canal between the car plug part and the car drum of the hearing aid user. The car plug part comprises a second microphone (3) arranged for transforming an acoustic signal in the volume into an electrical signal. The hearing aid comprises estimating means for estimating the effective size of the air leak between the inner volume and the surroundings based on the acoustical signal detected in said volume by said second microphone (3) from a known acoustical signal below 1000 Hz generated by the receiver. The hearing aid further comprises notification means for notifying the hearing aid user if the size range of the air leak is outside a predefined range.

Abstract: A computer-implemented method of identifying vascular territories in an imaging volume representing an anatomical region, including: obtaining, for each volume element of a plurality of volume elements into which the imaging volume is divided, arrival time data representing an estimated arrival time of a contrast agent at the volume element; defining one or more seed regions, each seed region associated with one of a plurality of vascular territories and containing seed volume elements for which the estimated arrival time does not exceed a threshold time; identifying, on the basis of the arrival time data, unassigned elements of the plurality of volume elements which are connected with a seed volume element; and assigning said unassigned elements of the plurality of volume elements to one of said vascular territories.